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Abstract
Purpose of Review Sepsis is a leading cause of death worldwide. Groundbreaking international collaborative efforts have 
culminated in the widely accepted surviving sepsis guidelines, with iterative improvements in management strategies and 
definitions providing important advances in care for patients. Key to the diagnosis of sepsis is identification of infection, 
and whilst the diagnostic criteria for sepsis is now clear, the diagnosis of infection remains a challenge and there is often 
discordance between clinician assessments for infection.
Recent Findings We review the utility of common biochemical, microbiological and radiological tools employed by clini-
cians to diagnose infection and explore the difficulty of making a diagnosis of infection in severe inflammatory states through 
illustrative case reports. Finally, we discuss some of the novel and emerging approaches in diagnosis of infection and sepsis.
Summary While prompt diagnosis and treatment of sepsis is essential to improve outcomes in sepsis, there remains no single 
tool to reliably identify or exclude infection. This contributes to unnecessary antimicrobial use that is harmful to individuals 
and populations. There is therefore a pressing need for novel solutions. Machine learning approaches using multiple diag-
nostic and clinical inputs may offer a potential solution but as yet these approaches remain experimental.
Keywords Infection · Sepsis · Diagnosis · Critical care
Introduction
The third consensus definition of sepsis is ‘life-threatening 
organ dysfunction caused by a dysregulated host response to 
infection’ and septic shock a subset of patients with a vaso-
pressor requirement and lactate > 2 mmol/L [1]. At its most 
severe, sepsis continues to have a high mortality. Agreed 
criteria to define sepsis are intended to identify patients 
early, allowing the prompt initiation of treatment, including 
sepsis care bundles, which may improve outcomes [2]. It 
also provides a common language for international research 
and outcome reporting [1]. The need for a third consensus 
definition points to the challenges underlying the diagno-
sis of sepsis and the evolution of our understanding of the 
pathophysiology of this disease and its mimics.
The first consensus definition, made in the 1990’s, uti-
lised one haematological and three clinical variables (tem-
perature, heart rate, respiratory rate and white blood cell 
count) to identify sepsis in those with infection [3]. These 
variables, which defined the systemic inflammatory response 
syndrome (SIRS), provided a useful starting point for stand-
ardising the diagnosis of sepsis but had some limitations. 
Foremost among these is that SIRS is found frequently in 
patients admitted to intensive care units (ICU) regardless of 
the reason for admission [4–7], yet still fails to identify some 
patients with severe infection causing significant organ dys-
function [8]. The most recent criteria characterise patients 
with sepsis as those with a change in SOFA (sequential 
organ failure assessment) score of 2 points or more within 
a 24-h time period in the presence of suspected infection. 
The argument in favour of this change is cited as improved 
predictive validity over SIRS for ICU mortality or prolonged 
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ICU stay. Further advocated is the  identification of  those 
patients with infection who are at risk of deterioration using 
clinical criteria (qSOFA) — two or more of altered mental 
state, tachypnoea (defined as a respiratory rate > 22 breaths 
per minute) or hypotension (defined as systolic blood pres-
sure < 100 mmHg) [1]. These criteria make the definition of 
sepsis clear and its diagnosis in the patient with an infection 
straightforward, since SOFA scores are readily calculable 
from routine examination and laboratory tests.
What is not easy is the diagnosis of infection. Indeed, 
the SEPSIS-3 task force specifically state that examining the 
definitions of infection was not ‘within the task force brief’. 
Datasets used to model the performance of the qSOFA and 
the new definition of sepsis contained patients with ‘sus-
pected infection’. There is no commentary on how the suspi-
cion of infection arises or what objective thresholds exist to 
make a diagnosis of infection, suspected or otherwise. Simi-
larly, the surviving sepsis guidelines seem to take the diag-
nosis of infection or suspected infection as read. ‘Diagnosis’ 
comes in third in the order of consideration after resuscita-
tion and screening for sepsis. Commentary on diagnostic 
and prognostic biomarkers of infection first appear some 18 
pages into these guidelines [2].
In this article, we aim to briefly summarise the utility of 
tools used to aid clinicians in the diagnosis of infection, and 
therefore in the diagnosis of sepsis.
Screening for Sepsis
The  2016 iteration of the surviving sepsis campaign guide-
lines recommends hospitals implement a sepsis screening 
system for acutely ill, high-risk patients [2]. The utility of 
sepsis screening tools, and their applicability, continues to 
be a subject of debate. Identifying the impact of a screening 
tool alone is challenging, as sepsis care bundles are often 
implemented alongside screening tools, perhaps explaining 
why this remains a ‘best practice statement’ in the Surviving 
Sepsis Campaign Guidelines. For example, in Levy et al.’s 
study on the impact of the surviving sepsis campaign in 
2010, participants were enrolled only if they already had 
suspected infection and met SIRS criteria for sepsis [9], 
meaning the impact of the screening tool itself could not 
be reviewed. Other data cited by the Surviving Sepsis Cam-
paign arise from quality improvement projects. Jones et al. 
reported a 12% absolute reduction in sepsis associated mor-
tality after the introduction of a 17-point sepsis screening 
tool [10], but there was promotion of specific interventions 
following screening in this study too. Damiani et al. under-
took a systematic review of such improvement programmes 
and found consistent reporting of improvement in sepsis 
outcomes [11].
The SEPSIS-3 task force noted that a patient found to 
meet qSOFA criteria should ‘prompt consideration of 
possible infection in patients not previously recognised 
as infected’ [12]. One potential drawback of qSOFA as a 
potential screening tool is that it was identified and tested 
using a dataset of patients already suspected of having infec-
tion [13]. The UK national screening committee notes that 
the purpose of screening is to offer a test to a population 
who ‘do not necessarily perceive that they are at risk of, or 
are already affected by, a disease or its complications’ [14]. 
Since qSOFA was initially validated in a group of patients in 
hospital with suspected infection and continues to be tested 
largely in this population, it arguably falls short on this defi-
nition. Indeed, members of the task force have subsequently 
stated that qSOFA is not a screening tool but should be used 
to identify those at risk of worse outcome from infection. 
Given the tools used by clinicians to diagnose infection, it 
may be preferential to use the formal definition of sepsis to 
predict poor outcome, since many of these tools will also 
calculate a formal SOFA score. Perhaps the exception is 
access to a readily available  PaO2 for patients outside critical 
care, although conversion models exist to substitute oxygen 
saturations  (SpO2) [15].
Can Clinicians Agree on Whether 
an Infection Is Present?
Table 1 provides brief details of presenting symptoms 
of three imagined case scenarios. They are intended to 
describe a typical presentation of acute pancreatitis (case 
1) and sepsis secondary to a complicated urinary tract 
infection (case 2). The details provided meet the qSOFA 
screening criteria that suggest we consider sepsis if we 
suspect infection. We intend to provoke suspicion of infec-
tion in both cases, noting that it appears more likely in 
case 2. Scenario 3 would satisfy the definition of sepsis; 
however, it is a case of systemic juvenile arthritis with 
evolving haemophagocytosis with no infectious trigger. 
We recognise that there will not be universal suspicion of 
infection and sepsis amongst physicians reading such case 
examples. In a survey of intensivists in 104 US hospitals, 
Stevens et al. found significant discordance in diagnosing 
pneumonia, with some physicians identifying pneumonia 
in 100% and others 0% of case vignettes presented to them 
[16]. Lopansri et al. found only moderate inter-observer 
agreement on the diagnosis of sepsis or SIRS in a multi-
centre cohort of patients with culture positive infection, 
disagreement was most pronounced in cases of respiratory 
infections [17], and Rhee et al. found similar disagree-
ment in their survey of US clinicians [18]. Similar results 
have been found in paediatric studies. Peltola et al. found 
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physician’s sensitivity of 38% for diagnosing influenza 
in a prospective study of 2288 children with respiratory 
infections [19] and in a prospective cohort study of nearly 
16,000 children with fever presenting to a hospital in Aus-
tralia, Craig et al. found a low sensitivity of physicians’ 
diagnosis of bacterial infection (10–50%) [20].
The reader may, or may not, consider infection possible 
in case 1, but suspicion of infection in cases of acute pan-
creatitis is high amongst clinicians and antibiotics are often 
prescribed [21]. The use of routine antibiotics in severe acute 
pancreatitis is not recommended as there is no evidence of 
efficacy, either in terms of mortality or reduction in the inci-
dence of infected necrosis [22]. However, as there is some 
evidence of efficacy in necrotising pancreatitis, international 
guidelines recommend the use of antibiotics where infection 
is suspected [23]. In what is a somewhat recurring theme in 
this subject area, no recommendations are given as to when 
or how to suspect infection. Given the most common cause 
of death in acute pancreatitis is infection [24], clinicians are 
left somewhat in a quandary with regards to antibiotics in 
this condition. The Surviving Sepsis Campaign guidelines 
recommend the initiation of antibiotics within one hour of a 
diagnosis being made or suspected. It seems likely that this 
time limit will expire prior to any complex cross-sectional 
imaging can be organised and reported, meaning antibiot-
ics are likely to be given before a diagnosis of necrotising 
pancreatitis can be confirmed or ruled out.
Diagnostic Value of Common Laboratory 
Biomarkers
Blood culture is the gold standard for diagnosis of blood 
stream infection but is limited by poor sensitivity and the 
required processing time. Challenges in clinical diagnosis 
and requirement for prompt diagnosis and treatment have 
led to reliance on biomarkers such as white blood cell 
count, C-reactive protein (CRP), and procalcitonin (PCT). 
Indeed, the first consensus sepsis definition incorporated an 
increased (> 12 ×  109 /L) or decreased (< 4 ×  109 /L) white 
blood cell count into the SIRS criteria [3]. However, the util-
ity of serum biomarkers to predict or exclude blood stream 
infection is debated, with many of the commonly used tests 
lacking sensitivity and specificity. In a recent retrospective 
cohort study, Marik and Stephenson reported white blood 
cell count to have a very poor predictive value for bacte-
raemia in patients presenting with suspected sepsis with an 
AUROC as low as 0.52 [25]. Siegel et al. found that 52% 
of patients presenting to the Emergency Department with 
proven blood culture positive bacteraemia had a normal 
white blood cell count as defined by the SIRS criteria [26]. 
In a meta-analysis of the value of diagnostic tests in febrile 
children, Van den Bruel et al. found white cell count to be of 
little diagnostic benefit in ruling out serious infection, with a 
negative likelihood ratio as low as 0.61 [27]. In a retrospec-
tive analysis of 1169 appendicectomies in a district general 
hospital, Panagiotopoulou et al. found neither raised CRP 
or white cell count as useful diagnostic markers for acute 
appendicitis. Whilst they found a raised white cell count to 
be relatively sensitive (84%), it was not specific (58%) and 
did not have a favourable negative predictive value (68%). 
The results were similar for CRP [28]. Warschkow et al. 
found similar results in their review of the routine blood tests 
of patients who had undergone open resection of colorectal 
cancer [29]. They found day 5 raised white cell count to have 
a sensitivity of 70% and specificity of 58% for inflammatory 
complications.
The neutrophil to lymphocyte count ratio has been con-
sistently reported to be a more accurate marker of physi-
ological stress than absolute white blood cell or neutrophil 
Table 1  Details of presenting symptoms of three imagined case scenarios
Scenario 1
A 54-year-old man with epigastric pain
Scenario 2
A 78-year-old woman with dysuria and frequency
Scenario 3
A 20-year-old woman with fever and rash
•   10-day history of epigastric pain and nausea
•   Evolving breathlessness in the 48-h preceding 
presentation
•   History of alcohol induced pancreatitis and 
ongoing alcohol excess
•   Temperature 38.5 °C, respiratory rate 28 bpm, 
HR 115 bpm,  SpO2 88% breathing air, blood 
pressure 94/65 mmHg
•   Inspiratory crackles and epigastric tenderness 
were found on examination
•   5-day history of suprapubic pain and dysuria
•   Evolving fatigue and dizzyness in the 48-h 
preceding presentation
•   Temperature 39.2 oC, respiratory rate 24 bpm, 
HR 133 bpm, SpO2 94% breathing air, blood 
pressure 78/55 mmHg
•   Bedside urinalysis positive for nitrite, leuko-
cytes and blood
•   14 day history of daily fever to 39 and 
fatigue
•   Effervescent pink rash on chest wall – 
non-blanching
•   Increasing shortness of breath over 
48 h
•   Reduced urine output
•   Temperature 39.5, Sp)2 93% on air, 
RR 30, HR 110, BP 84/65
•   History of joint pain as a child with 
steroid injection
Initial investigations
•   White cell count 18.3 ×  109/L (4–11)
•   Neutrophil count 12.6 ×  109/L (1.5–8.0)
•   CRP 128 mg/L (0–5)
Initial investigations
•   White cell count 23.9 × 109/L (4–11)
•   Neutrophil count 16.5 × 109 /L (1.5–8.0)
•   CRP 186 mg/L (0–5)
Initial investigations
•   White cell count 31 × 109/L (4–11)
•   Neutrophils 29 × 109/L (1.5–8.0)
•   CRP 338 mg/L
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counts [30, 31]. A rise of neutrophil count and fall in lym-
phocyte count is commonly encountered in systemic illness 
and is hypothesised to be due to the endogenous actions 
of cortisol and catecholamines. Furthermore, sepsis causes 
lymphocyte migration to inflammatory tissues and increased 
lymphocyte apoptosis resulting in a greater rise in neutrophil 
to lymphocyte count ratio when compared with other causes 
of physiological stress. A normal neutrophil to lymphocyte 
ratio is reported to be 2.15 and a level of 10 considered to 
be a threshold for the diagnosis of bacteraemia [32, 33]. 
In a prospective study of 1572 patients presenting to the 
Emergency Department, Ljungstrӧm et al. found neutrophil 
to lymphocyte count ratio to be superior to PCT and CRP 
for the diagnosis of bacterial sepsis (AUROC 0.68 vs 0.64 
vs 0.57, p < 0.05) and the diagnosis of bacterial infection, 
although the difference in AUROC did not reach statistical 
significant in the latter [34]. Neutrophil to lymphocyte count 
ratio is seen to be elevated in any form of severe physiologi-
cal stress and is not specific for the diagnosis of bacteraemia. 
This is recently evidenced by its application for predicting 
disease severity in patients with coronavirus disease 2019 
(COVID-19) [35]. In addition, neutrophil to lymphocyte 
count ratio is significantly less accurate in the diagnosis of 
sepsis in the critical care population in whom there is invari-
ably an elevated neutrophil to lymphocyte count ratio even 
in non-infected patients. Westerdijk et al. reported neutro-
phil to lymphocyte count ratio to have an AUROC of 0.66 
for predicting sepsis in critical care versus remarkably high 
AUROCs of 0.89 and 0.88 for CRP and PCT, respectively 
[36].
C-reactive protein (CRP) is an acute phase protein synthe-
sised in the liver following inflammatory stimuli, with con-
centrations rising within 12–24 h [37, 38]. Although a com-
monly used marker in critical illness, CRP lacks specificity 
for bacterial infection and is seen to rise in most other causes 
of inflammation. Serum CRP level may take up to 72 h to 
peak, contributing to diagnostic and surveillance challenges 
[39]. In a meta-analysis assessing the diagnostic accuracy 
of CRP in sepsis, Tan et al. found CRP to have a AUROC 
of 0.75 with a pooled sensitivity of 0.80 but a specificity of 
only 0.61 [40]. The level of CRP was reported to have little 
correlation with the severity of illness in sepsis. Conversely, 
CRP is the most utilised biomarker for predicting disease 
severity in pancreatitis due to its low cost and widespread 
availability [41]. A CRP level of > 150 mg/L is regarded 
as a threshold marker of pancreatitis severity with Khanna 
et al. reporting this cutoff level to have a 100% sensitivity 
and 81.4% specificity for necrotising pancreatitis [42]. CRP 
does not, however, consistently distinguish between sterile 
and infected pancreatic necrosis and is not recommended 
to be used as a marker to commence antimicrobial therapy. 
The CRP trend between two different time points is more 
efficacious with Póvoa et al. reporting a daily CRP variation 
of > 41 mg/L in critical care patients predicting bacterial 
infection with a sensitivity and specificity of 0.92 and 0.71, 
respectively [43]. Erythrocyte sedimentation rate (ESR) is 
an alternative non-specific test of systemic inflammation that 
remains in use in some centres, particularly for the surveil-
lance of rheumatological disorders. It demonstrates a slower 
rise than CRP and has been suggested to be inferior to PCT, 
CRP and WBC count in the diagnosis and prognosis of sep-
sis using the SEPSIS-3 criteria [44].
Procalcitonin (PCT) is a precursor to calcitonin. Its pro-
duction is upregulated in response to sepsis and has been 
suggested to reliably distinguish between bacterial infec-
tion and other inflammatory states [45]. PCT rises 2–3 h 
following infection and reaches a peak at 24 h. Although a 
faster rise than CRP, the delay in reaching peak concentra-
tion necessitates caution when using PCT as a sole marker 
of infection at initial presentation. Highest PCT levels are 
detected in gram-negative bacteraemia with only a mini-
mal elevation in fungal infection [46]. Given the increasing 
prevalence of fungaemia, PCT is a potentially useful bio-
marker to predict those who will not benefit from empirical 
antifungal therapy [46–48]. In a systematic review and meta-
analysis, Wacker et al. reported PCT to be a good biomarker 
to differentiate between sepsis and other non-inflammatory 
syndromes with an AUROC of 0.85 [49]. Pooled results 
from the several meta-analyses have reported overall sensi-
tivity and specificity ranges of 0.72 to 0.93 and 0.64 to 0.84, 
respectively, with positive and negative likelihood ratios of 
3.0 to 5.9 and 0.11 to 0.44 [50]. These data suggest a mod-
erate discriminatory ability between bacterial infection and 
non-infectious inflammatory states but a negative test cannot 
exclude infection. PCT may be useful in predicting infec-
tive versus non-infective pancreatic necrosis with Rau et al. 
reporting a threshold of > 1.8 ng/mL having a similar sensi-
tivity (0.95) and specificity (0.88) to US guided fine needle 
aspiration (FNA) [51]. Although subsequent research pre-
dicts a slightly lower sensitivity, these data have prompted 
international guidelines to suggest using PCT to aid in 
deciding whether to commence antimicrobial therapy [52, 
53]. PCT may be less effective in distinguishing between 
bacterial and viral infection with Kamat et al. reporting poor 
sensitivity (0.55) and only moderate specificity (0.76) in a 
systematic review and meta-analysis of 12 papers focused 
on serum PCT levels in patients with community-acquired 
pneumonia [54]. Similarly, PCT exhibits a lower diagnostic 
AUROC and sensitivity for predicting bacterial infection in 
patients with renal impairment (defined by an estimated glo-
merular filtration rate < 30 mL/min/1.72  m2) [55], immuno-
compromised patients [56] and in patients with autoimmune 
conditions [57].
Numerous studies have assessed the safety and effi-
cacy of discontinuing antimicrobial therapy when PCT 
concentration reaches < 1 ng/mL or falls by 65–90% from 
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peak values. They have demonstrated a reduction in total 
duration of antimicrobials (around 2 days) without a nega-
tive impact on length of stay and mortality rates [58–60]. 
Many of the antimicrobial courses in the PCT-guided 
groups remained > 7 days emphasising that more evidence 
is required to correlate this data with emerging evidence 
that shorter antibiotic courses may be appropriate for certain 
disease states [61].
The initial investigations in our theoretical cases empha-
sise the non-specific nature of commonly used biomarkers. 
The history consistent with urinary tract infection and raised 
inflammatory markers is highly predictive of infection in case 
2 with indicators of severe disease (e.g. hypotension) that 
may indicate sepsis. Similarly, the findings and investigations 
in the other scenarios also support the diagnosis of a signifi-
cant inflammatory insult that would prompt many clinicians 
to consider infection and prescribe empirical broad-spectrum 
antimicrobials for fear of missing the 1-h window. In scenario 
1, although the CRP has not exceeded the severity threshold 
of > 150 mg/L, the white blood cell count level would con-
tribute to severity prediction using both the Glasgow-Imrie 
and Ranson’s criteria [62, 63]. Readers may or may not con-
sider PCT to be useful in this case, but it is not commonly 
performed within the first hour of presentation. Similarly, 
in scenario 3, findings may suggest infection (and sepsis), 
although all cultures were consequently negative and a sig-
nificantly elevated ferritin (56,000 µg/L [10-120]) favours a 
diagnosis of Still’s disease [64].
Microbiological Diagnosis of Infection
In the absence of a suitable alternative test, detection of path-
ogens from blood culture samples remains the gold standard 
for diagnosing blood stream infection. Unfortunately, routine 
blood cultures may take over 72 h to yield a detectable organ-
ism with further time required to identify and test for antibi-
otic susceptibility. This timeframe is unacceptable in sepsis 
where delays in treatment worsen morbidity and mortality 
and contributes to the need for empirical, non-targeted anti-
biotic therapy [65]. A recent meta-analysis of seven studies 
including 22,655 patients with sepsis or septic shock identi-
fied that only 40.1% of patients had positive blood cultures 
[66]. This is more pronounced in the neonatal population 
where, even in symptomatic neonates, only 10 to 15% of 
blood cultures yield a positive causative result after excluding 
contaminants [67]. A multitude of factors may contribute to 
this poor diagnostic yield. For example, the lack of reliable 
diagnostic criteria for infection in sepsis means that many 
patients actually have non-infectious inflammatory states due 
to metabolic, neurological or inflammatory disorders [68]. 
Many patients are administered antibiotics prior to the devel-
opment of or worsening of sepsis and prior to blood culture 
sampling. Cheng et al. demonstrated an absolute difference 
in the proportion of positive blood cultures between pre- and 
post-antimicrobial testing of 12.0% [69]. This reduces the 
probability of pathogen detection [70]. Finally, many com-
mon pathogens, including some bacteria, viruses and fungi, 
are not detectable using conventional culture techniques and 
rely on surrogate markers such as urinary antigens and non-
specific fungal markers. Given the growing incidence of sep-
sis caused by atypical organisms this may become increas-
ingly problematic [71].
The culture of other fluids and samples, such as urine, 
sputum, cerebrospinal fluid, faeces, wound and skin swabs, 
are subject to the same significant time delays as blood 
culture making them unsuitable for the initial diagnosis of 
bacterial infection. Essentially any sample may be cultured 
to identify a causative organism but the results are very 
variable and often do not yield positive results even in the 
presence of severe sepsis (a now redundant term) [72, 73]. 
Simple bedside diagnostic tests tend to lack reliability to 
exclude infection. Mambatta et al. found the presence of 
nitrite and leukocyte esterase on urine dipstick analysis to 
only have a sensitivity of 23.31% and 48.5% respectively 
[74]. Sputum gram stain has been found to be useful in the 
aetiologic diagnosis of community acquired pneumonia but 
is not routinely used and further work is needed to ascertain 
the impact on clinical outcomes [75].
Novel techniques for pathogen detection may offer an 
encouraging alternative to conventional methods. Matrix-
assisted laser desorption ionization time-of-flight mass spec-
trometry (MALDI-TOF MS) is a rapid diagnostic technol-
ogy capable of accurately identifying bacteria, yeast, fungi, 
Nocardia and mycobacteria species as soon as growth on 
culture is detected [76]. It has been demonstrated to hasten 
the identification of pathogens by 17 to 34 h, thereby reduc-
ing the time taken for effective and optimal antimicrobial 
strategies in sepsis [77–83]. These studies also found that 
MALDI-TOF MS decreased the length of hospital stay by 
1.75 to 6 days [78, 82] and improved overall survival by 4 to 
9% [78, 83], emphasising the importance of early pathogen 
recognition. MALDI-TOF MS is currently unable to detect 
antimicrobial resistance mechanisms and therefore testing 
antibiotic susceptibility relies upon traditional laboratory 
techniques [76]. Research to identify spectral peaks that cor-
relate with enzymatic mechanisms of antimicrobial resist-
ance is ongoing and will further increase the value of this 
technology for tailoring antibiotic therapy [84, 85].
New systems incorporating the polymerase chain reac-
tion (PCR) for microbe amplification, prior to mass spec-
trometry (MS) detection, have been developed to rapidly 
accelerate the identification of clinically relevant bacteria 
and yeast species (turnaround time advertised as 6 to 8 h) 
with a higher diagnostic yield than blood culture [86]. 
Furthermore, microorganisms that do not reliably grow 
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in blood cultures may be detectable including Legionella 
pneumophila, Mycoplasma pneumoniae, Rickettsia typhi, 
Nocardia spp. and various fungi [87]. Makristathis et al. 
additionally reported that following prior antimicro-
bial therapy, positive results were detected in 82.9% of 
patients with PCR/MS versus only 41.5% with blood cul-
tures [88]. PCR methods enable detection of co-infection 
with bacteria and viruses which is a frequent phenom-
enon in community acquired pneumonia [89]. Initial con-
cerns regarding over-sensitivity of these tests due to PCR 
amplification have been addressed by introducing semi-
quantitative methods with an aim to identify and eradi-
cate contaminants. Although commercially available and 
useful for complementing and expediting microbiological 
diagnosis of sepsis, these techniques have not yet consist-
ently reached sufficient positive predictive value to replace 
conventional cultures [90]. They are also unable to identify 
more than a handful of markers of antibiotic resistance 
which is an essential factor in providing targeted therapy 
[91]. Although a promising step forward, these techniques 
have not yet reached the desired target of accurate detec-
tion of organisms with antibiotic susceptibility within a 1 
to 3-h window to allow targeted initial management.
PCR has been used in detection of viruses since the late 
1980s. For RNA viruses, a reverse transcriptase (RT) process 
is required to convert the single stranded RNA into com-
plementary DNA. RT-PCR is the frequently used method 
for detecting viruses due to its low cost, simplicity and high 
sensitivity [92]. It is limited by a high false positive rate due 
to contamination and the ability of RT-PCR to detect frag-
ments of non-viable viruses from a previous illness. Real-
time quantitative polymerase chain reaction (RT-qPCR) has 
become the gold standard for virus detection and facilitates 
quantification of sequences by measuring fluorescence emis-
sion during the amplification stage. This provides a high 
sensitivity and low detection limit [93]. In a sample size of 
519 people, Sundell et al. reported the detection of respira-
tory viruses in asymptomatic individuals was as low as 4.3% 
from nasopharyngeal swabs suggesting that positive results 
in symptomatic individuals are likely to be significant [94]. 
Although bacteria are the predominant causative pathogen 
for sepsis [95], viruses are often underdiagnosed with several 
studies detecting viral infection in up to one-third of adults 
with septic shock [96, 97]. Whilst there is no current recom-
mendation for the use of empirical antiviral therapy in sepsis, 
it may be prudent to screen for viral infection in patients 
with severe respiratory illness. This strategy has been widely 
applied during the COVID-19 pandemic which has mandated 
the widespread use of real-time PCR testing. Due to the rapid 
spread of the SARS-CoV-2 virus, rapid antigen lateral flow 
tests have provided an alternative testing strategy to deliver 
results in minutes rather than the several days required for 
PCR in most institutions. The low cost, speed and ease of use 
of antigen testing is an attractive method for guiding patient 
management and public health decisions but they lack the 
sensitivity of PCR, and many have not undergone stringent 
regulatory review. WHO guidance advises confirmation of 
positive tests using conventional PCR testing [98].
Future Role of biomarkers, machine learning 
and gene expression
The absence of an ideal infection or sepsis biomarker has led 
to the research of hundreds of novel tests [50, 99]. The most 
extensively investigated include IL6 [100], CD64 [101], prese-
psin [102], calprotectin [103], sTREM-1 [104] and pentraxin-3 
[105]. Unfortunately, many of these tests exhibit the same limi-
tations as conventionally used biomarkers and none have been 
robustly proven to be superior [99]. Presepsin and CD64 are the 
most promising biomarkers and are suggested to have a greater 
sensitivity and shorter time to peak levels than conventional 
biomarkers although larger studies are required [39, 106]. Stud-
ies into novel biomarkers are limited by diverse methodology 
and small study size with many only having been assessed in 
populations of < 300 patients. Larger, multi-centre studies are 
required that account for the heterogeneity of sepsis, before any 
of these tests change global clinical practice.
Combining several biomarkers has been shown to improve 
the diagnostic accuracy in sepsis [107, 108]. Han et al. dem-
onstrated the combination of PCT and CRP to have a high 
ability to discriminate between bacterial sepsis and non-
infectious inflammation in the ICU [109]. In a systematic 
review and meta-analysis including 2661 patients, Ruan et al. 
reported the same combination to have a higher sensitivity 
(0.94), AUROC (0.96) and lower negative likelihood ratio 
(0.89) than CRP or PCT alone in the diagnosis of neona-
tal sepsis [110]. Similarly, the combination of CD64 and 
CRP was found to be more sensitive for neonatal sepsis than 
either measure alone [111]. Combination biomarker panels 
may also perform better than single biomarkers in predicting 
prognosis in septic patients [112, 113]. The integration of 
clinical information into these biomarker panel algorithms 
may further improve the ability to differentiate between sep-
sis and non-infectious inflammatory states. In a multi-centre 
prospective study, Mearelli et al. developed a predictive algo-
rithm incorporating age, SOFA score, recent antimicrobial 
therapy, hyperthermia and a biomarker panel (white blood 
cell, CRP, PCT, presepsin, soluble phospholipase A2 group 
IIA & soluble interleukin-2 receptor α) which demonstrated 
an high negative predictive value for ruling out sepsis in 
the Emergency Department [108]. The same authors subse-
quently demonstrated this algorithm to be superior to qSOFA 
alone in the prognostication of patients with sepsis [114].
The widespread application of electronic medical records 
(EMR) in modern clinical practice provides a unique 
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opportunity to analyse large amounts of data within machine 
learning models. The combination of novel biomarkers with 
EMR data is suggested to be capable of the early diagnosis 
and differentiation of sepsis from its mimics [115]. A recent 
meta-analysis by Islam et al. reported machine learning 
approaches to perform better than conventional scoring sys-
tems for predicting sepsis [116]. Machine learning models are 
described as being either left-aligned or right-aligned. Left-
aligned models are used to predict the onset of sepsis from 
a fixed point in time — for example from the arrival of the 
patient into the Emergency Department [117]. The predomi-
nant aim of this approach is to expedite the diagnosis and 
initiation of sepsis treatment to avoid delay. Right-aligned 
models use large amounts of data to continually predict the 
development of sepsis following a distinct period of time — 
effectively the ability to diagnose sepsis before it is clinically 
evident [118]. The potential value of machine learning algo-
rithms is clear. Fleuren et al. have recently demonstrated in 
a systematic review and meta-analysis that machine learning 
models may accurately predict sepsis ahead of time when 
analysing retrospective data [118]. Unfortunately, signifi-
cant heterogeneity exists in study methodology, reducing the 
clinical utility of these models. Additionally, most models 
have been tested using the MIMIC database which is a freely 
available clinical database of patients from the Beth Israel 
Deaconess Medical Center in Boston, USA [119]. This poten-
tially means the models have limited applicability in low- and 
middle-income countries. Nevertheless, this is an area that is 
likely to expand dramatically in the coming years. Prospec-
tive trials are required to confirm the clinical utility of these 
models.
The role of host gene response to sepsis is another avenue 
of research to identify a sepsis signature. These techniques 
aim to identify specific RNA biomarkers that arise in response 
to sepsis but not other causes of inflammation. Two such 
assays are commercially available, the SeptiCyte Lab [120] 
and the Sepsis MetaScore [121], which have recently been 
prospectively validated in the ICU population. The AUROC 
results for diagnosis of sepsis versus non-infectious inflam-
mation was 0.8 for the Sepsis MetaScore and 0.68 for the 
SeptiCyte Lab [122]. Although this method is not routinely 
deployed, these findings are encouraging for the role of preci-
sion, gene-based medicine in the future of sepsis treatment.
Role of Diagnostic Imaging in Sepsis
Identifying the source of sepsis using diagnostic imaging 
is essential for providing targeted antimicrobial therapy, 
disease surveillance and interventional source control. The 
source of sepsis can guide the clinician to the likely causa-
tive pathogen and guide antibiotic class and subtype depend-
ing upon regional resistance patterns. In the critically unwell 
patients, conventional history providing clues as to the ori-
gin of infection is often unavailable leading to the reliance 
on septic screens including microbiological cultures and 
diagnostic imaging. Imaging will also enable diagnosis of 
sepsis mimics, such as acute pulmonary embolus and acute 
pancreatitis, which require alternative management and can 
avoid the unnecessary administration of antimicrobials. The 
optimal imaging modality is dependent upon the suspected 
source and balanced against the risks of cumulative radiation 
exposure and moving critically unwell patients.
The chest radiograph (CXR) is the most commonly per-
formed radiological investigation in sepsis [123] which is 
unsurprising considering respiratory infections are by far the 
most common source [95]. In many centres, CXR is regu-
larly performed to confirm the position of medical devices, 
such as nasogastric tubes and central venous catheters, 
allowing for the incidental identification and surveillance 
of pathology. Unfortunately, many features of pulmonary 
consolidation are non-specific for infection and the quality 
of portable imaging in unwell patients further worsens its 
performance [124]. Airspace opacities on CXR in ICU may 
reflect infection, atelectasis, oedema, haemorrhage, inflam-
mation, drug or transfusion reaction or acute respiratory 
distress syndrome [125]. Winkler et al. in a meta-analysis 
including 543 patients found CXR to only have a sensitivity 
of 49% for identifying causative pathology in the ICU [126]. 
Additionally, the risk of cumulative radiation exposure con-
tinues to be a concern in patients with long term critical 
illness. Machine learning has been reported to increase the 
diagnostic capability of CXR although is not widely applied. 
In a systematic review and meta-analysis, Li et al. reported 
deep learning algorithms to perform with high accuracy for 
the detection of pneumonia with an AUROC of 0.99 and 
the ability to differentiate viral from bacterial pneumonia 
with an AUROC of 0.95 [127]. Recent studies have applied 
machine learning to CXR interpretation in the COVID-19 
pandemic with encouraging results [128].
Recent technological advances in the quality and portabil-
ity of ultrasound devices have led to the widespread use of 
point of care ultrasound to assess the lung parenchyma. Sev-
eral systematic reviews and meta-analyses have found lung 
US to be superior to CXR for the diagnosis of pneumonia 
[126, 129–133]. Serial assessments may be performed with-
out repeated exposure to ionising radiation. However, ultra-
sound is limited to the identification of pathology extending 
to the lung peripheries due to the high acoustic impedance 
of air upon ultrasound waves. Similarly, ultrasound is highly 
user dependent, requires dedicated training and is time con-
suming for busy clinicians leading to continued reliance on 
CXR and computerised tomography (CT) imaging [134].
Ultrasound is recommended as the first line imaging 
modality in suspected biliary tree pathology [135]. It is 
reported to have a sensitivity of 81% for the diagnosis of 
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acute cholecystitis and 85–95% for the detection of biliary 
dilatation [136, 137]. Only if the ultrasound is equivo-
cal should further imaging such as magnetic resonance 
cholangiopancreatography (MRCP) or cholescintigraphy 
be performed.
Ultrasound, in the form of echocardiography, is the 
imaging modality of choice in suspected infective endocar-
ditis. 2D transthoracic echocardiography (TTE) is invaria-
bly the initial investigation due to being non-invasive, low 
cost and portable with a sensitivity of 70% and specificity 
of 90% for native valve infective endocarditis [138, 139]. 
Transoesophageal echocardiography (TOE) is superior to 
TTE with a sensitivity of 96% but at the expense of being 
an invasive procedure with significant potential complica-
tions [138, 140]. The sensitivity of both modalities falls 
in the setting of prosthetic valve endocarditis (TTE 50% 
versus TOE 92%) but it remains an important investigation 
to assess ventricular size, performance and valvular dys-
function [141]. Whilst a normal TOE is highly suggestive 
of a negative diagnosis of endocarditis, it cannot unequivo-
cally be excluded and current guidance recommends that a 
repeat TOE should be performed after 7–10 days in cases 
with a high index of suspicion [142]. Diagnosis may be 
particularly challenging with prosthetic valves (infective 
endocarditis versus thrombus versus pannus), intracardiac 
devices, small vegetations, abscesses and in patients with 
pre-existing valvular lesions such as mitral valve prolapse 
or degenerative calcific disease. In challenging cases, 
modern alternative imaging techniques may be deployed 
such as multi-slice computed tomography (MSCT), mag-
netic resonance imaging (MRI), 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET)/CT or other 
functional imaging techniques [139].
CT has emerged as the gold standard investigation for 
many potential sources of infection. It is highly sensitive 
and specific for the diagnosis of pneumonia and enables 
differentiation of infective patterns including focal, lobar, 
bronchopneumonia, interstitial, ground glass, nodular, tree-
in-bud and halo sign opacities. These pattern subtypes may 
provide clues as to the likely causative organisms and guide 
further investigation [143]. CT is suggested to reduce the 
overdiagnosis of pneumonia when compared with CXR, 
therefore lowering the inappropriate administration of anti-
microbial agents [144]. Incidental radiological findings, such 
as pulmonary nodules, may be seen in up to one third of 
elderly patients undergoing imaging for pneumonia provid-
ing an opportunity to diagnose and treat unexpected pathol-
ogy [145]. In a case series of patients with CXR diagnosed 
community acquired pneumonia admitted to the ICU, Karhu 
et al. found CT to yield new findings in 58.5% of patients. 
Of these patients, 76.5% subsequently underwent further 
diagnostic or therapeutic interventions based upon the CT 
findings [146].
CT is the diagnostic modality of choice for peritonitis. In 
a retrospective analysis of 251 patients with post-operative 
sepsis, Bader et al. found CT to have a diagnostic sensitiv-
ity of 97.2% when compared with conventional radiogra-
phy (66.2%) and US (44.3%) [147]. It can readily identify 
intra-abdominal infection in ICU patients who have sus-
tained major trauma; a cohort who invariably have signs of 
systemic inflammatory response with or without infection 
[148]. Furthermore, CT can accurately identify intra and 
retroperitoneal collections and guide drainage to avoid the 
requirement for invasive surgery. Although the safety and 
success rate of percutaneous drainage of intra-abdominal 
collections was conventionally considered to be safer with 
CT compared with ultrasound [149], many modern tech-
niques will use both modalities to enhance outcomes [150]. 
CT-guided fine needle aspiration (FNA) is the gold stand-
ard for diagnosing infected pancreatic necrosis but is not 
frequently deployed due to the high rate of false negative 
findings [52]. In the context of severe acute pancreatitis, 
retroperitoneal gas is considered to be indicative of infection 
but has a low negative predictive value [151]. This further 
adds to the dilemma of diagnosing pancreatic infection and 
promotes the excessive use of empirical antimicrobials.
The high diagnostic utility of CT must be balanced 
against the risk of transporting acutely unwell patients and 
the cumulative risk of cancer due to radiation exposure. 
Radiation dosage depends upon the type of CT but is esti-
mated to range from 1–15 millisieverts (mSv) [152]. The 
use of CT imaging in children has been found to triple the 
risk of developing leukaemia and brain tumours [153, 154]. 
In adults, much of the large population data suggesting the 
increased cancer risk due to low-level radiation exposure is 
derived from atomic bomb survivors [155] and workers in 
the nuclear industry [156]. For context, these sub-groups 
received radiation doses ranging from 5 to 20 mSv which 
is the equivalent of 1 to 2 CT scans. Radiation is thought 
to contribute to 2% of all deaths in this group. Based upon 
these findings, Shao et al. conducted a retrospective cohort 
study assessing 56,050 cases of thyroid cancer, leukaemia 
and non-Hodgkin lymphoma (NHL) in Taiwan and identi-
fied a small but significant increase in risk in patients under 
45 exposed to medical radiation [152]. The odds ratios for 
thyroid cancer, leukaemia and NHL for all populations 
were 2.55, 1.55 and 1.05, respectively. There was a three-
fold increase in NHL in individuals aged under 45. Whilst 
the individual risk is low, the increased prevalence of CT 
imaging is likely to have an impact at a public health level.
FDG-PET/CT has emerged as a useful second line inves-
tigation in patients with sepsis of unknown origin and Staph-
ylococcus aureus bacteraemia. Areas of active infection are 
identified as abnormal areas of glucose metabolism due to 
increased glycolysis by activated white blood cells [157]. 
FDG-PET/CT exposes the patient to less radiation than a 
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CT scan of the abdomen and pelvis with contrast and can 
identify many potential foci of infection within one inves-
tigation. Whilst potentially appealing, its use is limited by 
cost and required reporting time. The cost of PET/CT in the 
UK is £909 compared with around £140 for a CT scan [158]. 
The diagnostic advantage and cost-effectiveness will need 
to be justified prior to PET/CT being offered on a routine 
basis. Recent statistics suggest that the median timeframe 
from imaging request to being performed is 7 days with a 
further 2 days required for reporting [159]. This delay is 
likely to be considered unacceptable for critically unwell 
patients and promotes continued reliance on conventional 
imaging techniques.
In the absence of conclusive radiological diagnosis or 
if a patient is too unstable for imaging, bedside diagnostic 
laparoscopy may yield important information and negate the 
requirement for non-therapeutic laparotomy. Alemanno et al. 
recently reviewed 129 patients that underwent bedside diag-
nostic laparoscopy within their ICU, including 25 patients 
with unexplained sepsis. Findings were compared against 
154 ICU patients who underwent exploratory laparotomy in 
the operating suite. They conclude bedside diagnostic lapa-
roscopy in the ICU setting can be considered an option for 
cases with suggestive, but non-conclusive, laparotomy or 
radiological results, or in the rare case in which it is unsafe 
to transfer a critically ill patient to the radiology department 
[160]. Although large scale studies will be difficult to justify, 
diagnostic laparoscopy either at the bedside or in the operat-
ing department remains a consideration in individual cases.
Conclusions
The prompt recognition and targeted treatment of sepsis is 
essential to improve clinical outcomes. We have considered 
the role of screening tools, clinical assessment, biomark-
ers, microbiology and imaging in the diagnosis of infec-
tion and highlighted the strengths and limitations associ-
ated with each. To date, there is no diagnostic tool able to 
rapidly identify or exclude infection. The lack of a reliable 
diagnostic tool contributes to the high quantities of broad-
spectrum antimicrobial therapy used globally and is likely 
to lead to under-recognition (and over-treatment) of non-
infectious inflammatory states. Given the increasing preva-
lence of antibiotic resistance, there is an ever-pressing need 
for novel solutions. Combining machine learning models 
with biomarkers, gene markers and EMR data may improve 
the utility of screening tools but requires further work. The 
identification and management of sepsis continues to rely on 
thorough patient assessment and sound clinical judgement. 
Novel techniques should complement, not replace, these fun-
damental elements of patient care.
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